A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT07072169 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: ABO2203 Injection

Sponsor

Ruijin Hospital